Summary
Abbott Laboratories reported strong top-line growth in the second quarter and first half of 2022, with total net sales increasing by 10.1% and 15.9% respectively, excluding the impact of foreign exchange. This growth was largely driven by a significant surge in demand for its COVID-19 diagnostic tests, particularly within the Rapid Diagnostics segment, which saw a 70.4% increase in sales (excluding FX) in the first half. Excluding COVID-19 testing sales, overall net sales still demonstrated resilience, growing by 4.1% in Q2 and 1.7% in the first half on an organic basis. The company experienced notable growth in its Medical Devices segment, particularly in Diabetes Care driven by the FreeStyle Libre continuous glucose monitoring system. However, the Nutritional Products segment faced headwinds, notably due to a voluntary infant formula recall in the U.S. impacting U.S. Pediatric Nutritionals sales significantly. Despite these challenges and a negative impact from foreign exchange due to a strong U.S. dollar, Abbott maintained healthy profitability with improved gross profit margins.
Financial Highlights
51 data points| Revenue | $11.26B |
| Cost of Revenue | $4.93B |
| Gross Profit | $6.32B |
| R&D Expenses | $684.00M |
| SG&A Expenses | $2.76B |
| Operating Expenses | $8.88B |
| Operating Income | $2.38B |
| Interest Expense | $132.00M |
| Net Income | $2.02B |
| EPS (Basic) | $1.15 |
| EPS (Diluted) | $1.14 |
| Shares Outstanding (Basic) | 1.75B |
| Shares Outstanding (Diluted) | 1.77B |
Key Highlights
- 1Total net sales grew 10.1% in Q2 2022 and 15.9% in the first six months of 2022 (excluding foreign exchange), primarily driven by COVID-19 diagnostic sales.
- 2Excluding COVID-19 testing sales, Abbott's total net sales increased by 4.1% in Q2 and 1.7% in the first half, indicating underlying business strength.
- 3The Rapid Diagnostics segment was a key growth driver, with sales up 70.4% in the first half (excluding FX), fueled by COVID-19 tests.
- 4Medical Devices segment showed robust growth (9.4% excluding FX in H1), with Diabetes Care (FreeStyle Libre) and Electrophysiology being standout performers.
- 5Nutritional Products sales declined 7.4% in Q2 and 7.2% in the first half (excluding FX), significantly impacted by a voluntary infant formula recall in the U.S.
- 6Gross profit margin improved to 51.7% in Q2 and 52.8% in H1 2022, up from 46.7% and 49.9% respectively in the prior year, partly due to the non-recurrence of 2021 restructuring charges.
- 7Foreign exchange headwinds unfavorably impacted international sales due to a strong U.S. dollar, decreasing total sales by 4.2% in Q2 and 3.9% in the first half.